湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年年度股东大会的 湖南湘军麓和律师事务所 2023 年年度股东大会法律意见书 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年年度股东大会的法律意见书 致：南华生物医药股份有限公司 法律意见书 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 二○二四年五月 地址：湖南省长沙市芙蓉区远大一路 280 号湘域相遇 B 座 4 楼、8 楼及 C 座 4 楼 联系电话：(0731) 84587101 / 84587102 网址：www.xjlhlawyer.com 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）和中国证券监督管理委员会发布的《上市公司 股东大会规则》（以下简称"《股东大会规则》"）、《深圳证券交易所上市公司股东 大会网络投票实施细则》（以下简称"《网络投票实施细则》"）等有关规定，湖南 湘军麓和律师事务所（以下简称"本所"）接受南华生物医药股份有限公司（以 下简称"公司"）的聘请，指派陈琳律师、向思律师（以下简称"本所律师"）出 ...

证券代码：000504 证券简称：南华生物 公告编号：2024-033 南华生物医药股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示: 1.本次股东大会存在否决提案的情形，未通过提案为：《关于使用闲置资金 进行委托理财暨关联交易的提案》； 2.本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （2）网络投票时间：2024年5月24日（星期五）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2024年5月24日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2024年5月24日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票相结合 4.会议召集人：公司第十一届董事会 5.会议主持人：董事长杨云先生 6.会议召开的合法合规性：本次股东大会会议召开符合《公司法》《证券法》 《上市公司股东大会规则》等法律、法规和 ...

的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、基本情况 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）分别于2024 年4月8日、2024年4月24日召开了第十一届董事会第十九次会议、2024年第一次 临时股东大会，审议通过了修订《公司章程》及办理注册资本等变更登记的相关 议题，具体内容详见公司于2024年4月9日、2024年4月25日在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 二、工商变更登记完成情况 公司已于近日完成了注册资本的工商变更及章程备案手续，并取得了湖南省 市场监督管理局换发的《营业执照》，具体登记信息如下： 证券代码：000504 证券简称：南华生物 公告编号：2024-032 南华生物医药股份有限公司 关于变更注册资本、修订《公司章程》暨完成工商变更登记 1.名称：南华生物医药股份有限公司； 2.注册资本：叁亿叁仟零贰万叁仟零玖拾捌元整； 3.类型：其他股份有限公司（上市）； 4.成立日期：1991年10月18日； 5.法定代表人：杨云； 6.住所：长沙市高新区岳麓西大道1698号麓谷科技 ...

（一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 证券代码：000504 证券简称：南华生物 公告编号：2024-031 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2024年5月13日、2024年5月14日、2024 年5月15日连续三个交易日内收盘价格跌幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 1.前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 4.不存在涉及要参照相关公告格式作出说明和披露的其他事项； 5.本公司不存在需要根据深交所《股票上市规则》等有关规定应予以披露而 未披露的事项； ...

南华生物医药股份有限公司 股票交易异常波动公告 证券代码：000504 证券简称：南华生物 公告编号：2024-030 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2024年5月7日、2024年5月8日、2024 年5月9日连续三个交易日内收盘价格涨幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 1.前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 4.不存在涉及要参照相关公告格式作出说明和披露的其他事项； 公司控股股东湖南省财信产业基金管理有限公司（以下简称"财信产业基 金"）、公司间接控股股东湖 ...

Financial Performance - The company's operating revenue for 2023 was CNY 136,790,924, representing a decrease of 31.72% compared to CNY 200,345,457 in 2022[24]. - The company has reported a significant decline in revenue, with a drop of approximately CNY 63,554,533 from the previous year[24]. - The net profit attributable to shareholders of the listed company for 2023 is ¥28,172,625.5, a decrease of 126.15% compared to the previous year[25]. - The operating income for 2023 is ¥136,790,924.97, down from ¥200,345,457.02 in 2022, representing a decline of approximately 31.6%[28]. - The net cash flow from operating activities for 2023 is ¥36,276,713.5, a significant decrease of 78.20% compared to the previous year[25]. - The total assets at the end of 2023 amount to ¥771,382,516, reflecting a 39.40% increase from ¥553,064,727 in 2022[25]. - The net assets attributable to shareholders of the listed company increased to ¥256,941,198, a substantial rise of 1,734.17% compared to ¥13,771,203.6 in 2022[25]. - The basic and diluted earnings per share for 2023 are both -¥0.09, indicating a 125.00% decline from -¥0.04 in 2022[25]. - The company reported a total of ¥14,253,206.95 in non-recurring gains and losses for 2023, compared to ¥8,899,505.35 in 2022[34]. - The company reported a total revenue of CNY 136.79 million in 2023, a decrease of 31.72% compared to CNY 200.35 million in 2022[61]. - The revenue from the biopharmaceutical segment was CNY 101.61 million, down 28.80% year-on-year, while the energy-saving and environmental protection segment generated CNY 34.97 million, a decline of 39.17%[62]. - The gross margin for the biopharmaceutical sector was 74.88%, while the energy-saving technology service sector had a gross margin of 48.06%[64]. Strategic Focus and Business Model - The company has shifted its main business focus from real estate and publishing to biomedicine and cell technology services since 2015[23]. - The company has undergone a strategic adjustment in its major shareholder structure, with the largest shareholder holding 25.58% of the total shares[23]. - The company has maintained its operational control under the Hunan Provincial Government despite changes in its shareholder structure[23]. - The company has developed a dual main business model of "biomedicine + energy-saving and environmental protection," with over 70 patents and software copyrights[57]. - The biopharmaceutical segment primarily provides cell medical services, including stem cell and immune cell storage and testing, in collaboration with hospitals and clinical research institutions[42]. - The company is focusing on the development of cutting-edge medical technologies such as vaccines, biotherapy, and precision medicine[40]. - The company aims to break through technological bottlenecks in high-end medical equipment and enhance its capabilities in cell therapy technologies[40]. - The company plans to strengthen the collaboration between production, learning, and research to accelerate the transformation and clinical application of related technologies[40]. Research and Development - R&D expenses increased by 25.86% to CNY 12,567,051.06, reflecting increased investment in research and development[75]. - The company has completed several R&D projects aimed at optimizing production processes and enhancing safety in stem cell preparation[76]. - The establishment of a serum-free culture system for umbilical cord mesenchymal stem cells has been completed, improving safety and production efficiency[76]. - The company is expanding its market share in the immune cell industry by developing NK cell storage technology[76]. - Ongoing research on the anti-aging effects of umbilical cord mesenchymal stem cells and NK cell exosomes is being conducted[76]. - The company has developed a new technology for the treatment of high-concentration liquor wastewater, achieving a total nitrogen removal rate of over 90%[79]. - The company has invested heavily in research and development for wastewater treatment technologies, establishing a proprietary intellectual property system[54]. Market and Industry Trends - The stem cell industry in China is expected to exceed 30 billion yuan by 2026, indicating significant market potential[37]. - The compound annual growth rate (CAGR) for China's environmental protection industry is projected to reach 12% from 2022 to 2027, with revenue expected to surpass 440 billion yuan by 2027[38]. - The total output value of China's energy-saving and environmental protection industry is anticipated to exceed 19 trillion yuan by 2027[38]. - The Chinese government has implemented multiple policies to support the development of the biopharmaceutical industry, particularly in stem cell and regenerative medicine[39]. - The regulatory framework for stem cell therapy in China is gradually being established, promoting industry growth[37]. Governance and Compliance - The company ensures strict compliance with information disclosure laws, providing timely and accurate information to shareholders[128]. - The company has established a complete and independent personnel system, ensuring that all employees are contracted directly with the company[133]. - The company has a dedicated financial department, ensuring independent financial decision-making and tax compliance[135]. - The company has committed to maintaining its independence and ensuring that its operations, assets, and financials remain distinct from any controlling parties[192]. - The internal control audit report received a standard unqualified opinion, reflecting the reliability of the company's financial practices[182]. Future Outlook and Guidance - The company aims to become a leading biotechnology company by focusing on high-quality development in stem cells and immune cells, while also making breakthroughs in medical device trade and skincare products in 2024[106]. - The company provided guidance for 2024, projecting a revenue growth of 10% to 1.32 billion yuan[139]. - New product launches are expected to contribute an additional 200 million yuan in revenue in 2024[139]. - The company plans to increase its marketing budget by 25% in 2024 to support new product launches and market penetration[139]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[199]. Risks and Challenges - The company faces a significant risk due to a declining birth rate in China, with rates of 7.52‰, 6.77‰, and 6.40‰ over the last three years[111]. - The company is exposed to regulatory and policy risks, as well as technology development risks, which could impact its operations if it fails to adapt to new regulations[112]. - Financial risks include fluctuations in gross margin and net profit, which could arise from changes in business income structure and operational performance[115]. - The competitive landscape in the energy-saving and environmental protection industry is intensifying, with many new entrants and increasing pressure from existing competitors[114].

Financial Performance - The company's revenue for Q1 2024 was ¥25,973,854.69, a decrease of 25.23% compared to ¥34,739,572.68 in the same period last year[5] - The net loss attributable to shareholders was ¥2,770,653.53, representing a 40.21% increase from a loss of ¥1,976,045.11 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0084, a decrease of 33.33% from -¥0.0063 in the same period last year[5] - Net loss for Q1 2024 was CNY -2,846,531.87, compared to a profit of CNY 437,868.11 in Q1 2023, indicating a significant decline in profitability[20] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.0084, compared to CNY -0.0063 in the previous year[20] Cash Flow - The net cash flow from operating activities was -¥1,504,744.35, a significant decline of 779.35% from ¥221,498.68 in the same period last year[5] - Cash inflow from operating activities was CNY 40,257,981.62, down 27.8% from CNY 55,798,690.84 in Q1 2023[21] - The net cash flow from investment activities was -118,821,316.99, a substantial increase in losses compared to -9,858,235.23 in Q1 2023[23] - The net cash flow from financing activities was -160,857,327.41, worsening from -3,440,558.04 in Q1 2023[23] - The total cash and cash equivalents at the end of Q1 2024 stood at 212,597,686.65, compared to 205,040,966.14 at the end of Q1 2023[23] Assets and Liabilities - Total assets decreased by 20.75% to ¥611,302,774.92 from ¥771,382,516.09 at the end of the previous year[5] - The total liabilities decreased to CNY 309,475,438.53 from CNY 466,708,647.83 in the previous year, indicating improved financial stability[19] - The total equity attributable to shareholders of the parent company was CNY 254,170,544.84, a slight decrease from CNY 256,941,198.37 year-over-year[19] Operational Costs - Total operating costs for Q1 2024 were CNY 29,981,563.79, down 16.4% from CNY 35,814,358.27 year-over-year[19] - Research and development expenses for Q1 2024 were CNY 2,184,441.44, slightly down from CNY 2,197,527.49 in the same period last year[19] - Sales expenses decreased to CNY 7,414,026.52, a reduction of 15.2% compared to CNY 8,743,639.48 in Q1 2023[19] - Management expenses were CNY 10,585,520.54, down from CNY 11,823,853.16 year-over-year, reflecting a cost control strategy[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,387[11] - The company issued 18,449,197 shares in 2023, raising a total of approximately ¥276 million, with a net amount of ¥271 million after deducting issuance costs[12] - The company has no preferred shareholders or related party transactions among the top shareholders[12] Inventory and Current Assets - The company's inventory increased by 33.33% to ¥14,212,949.89 from ¥10,660,296.88, indicating a rise in engineering materials[8] - Other current assets surged by 224.43% to ¥23,453,184.31 from ¥7,229,117.81, attributed to increased bank wealth management purchases[8] - Total current assets decreased from ¥654.85 million to ¥497.83 million, a decline of approximately 24%[15]

证券代码：000504 证券简称：南华生物 公告编号：2024-015 南华生物医药股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示: 1.本次股东大会未出现否决提案的情形； 2.本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2024年4月24日下午15:00 （2）网络投票时间：2024年4月24日（星期三）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2024年4月24日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2024年4月24日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票相结合 4.会议召集人：公司第十一届董事会 （二）股东出席会议的整体情况： 1.总体出席情况 通过现场和网络投票的股东7人，代表股份158,73 ...

湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2024 年第一次临时股东大会的 法律意见书 地址：长沙市芙蓉区远大一路 280 号湘域相遇 B 座 4 楼、8 楼，C 座 4 楼 电话：（0731）84587101 84587102 传真：（0731）84587100 网址：http://www.xjlh.lawyer 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 二○二四年四月 湖南湘军麓和律师事务所 临时股东大会法律意见书 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2024 年第一次临时股东大会的法律意见书 致：南华生物医药股份有限公司 本法律意见书仅供公司本次会议之目的使用，不得被任何人用于其他任何目 的。本所律师同意将本法律意见书随公司本次会议决议一起予以公告。 一、本次会议的召集、召开程序 （一）本次会议的召集 经查验，本次会议由公司第十一届董事会第十九次会议决定召开并由董事会 召集。公司董事会于 2024 年 4 月 9 日在《中国证券报》《证券时报》《证券日报》 《上海证券报》和巨潮资讯网上公开公布了《关于召开 2024 年第一次临时股东 湖 ...

简式权益变动报告书 上市公司名称：南华生物医药股份有限公司 股票上市地点：深圳证券交易所 股票简称：南华生物 南华生物医药股份有限公司 股票代码：000504 信息披露义务人：重庆国际信托股份有限公司 住所：重庆市渝北区嘉州路 88 号 33 层、34 层、3501-3511 室 通讯地址：重庆市渝北区嘉州路 88 号 33 层、34 层、3501-3511 室 股份变动性质：股份增加 签署时间：2024 年 4 月 1 | 第一节 | 释义 4 | | | --- | --- | --- | | 第二节 | 信息披露义务人介绍 5 | | | 第三节 | 权益变动目的 7 | | | 第四节 | 权益变动方式 8 | | | 第五节 | 前六个月内买卖上市交易股份的情况 | 10 | | 第六节 | 其他重大事项 11 | | | 第七节 | 信息披露义务人声明 | 12 | | 第八节 | 备查文件 | 13 | | | 附表：《南华生物医药股份有限公司简式权益变动报告书》 14 | | 信息披露义务人声明 一、本简式权益变动报告书（以下简称"本报告书"）系依据《中华人民共和 国证券法》（以下简称"《证券 ...